Prosecution Insights
Last updated: November 20, 2026
Application No. 18/773,675

OINTMENT CONTAINING AN OXAZOLE COMPOUND

Non-Final OA §103§DOUBLEPATENT
Filed
Jul 16, 2024
Priority
Dec 28, 2015 — JP 2015-256784 +4 more
Examiner
JAVANMARD, SAHAR
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Otsuka Pharmaceutical Co., Ltd.
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
492 granted / 756 resolved
+5.1% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
55 currently pending
Career history
803
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
46.7%
+6.7% vs TC avg
§102
14.6%
-25.4% vs TC avg
§112
16.2%
-23.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 756 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims This Office Action is in response to Applicant's Restriction Requirement remarks filed on July 16, 2024. Claim(s) 1-9 are pending and examined herein insofar as they read on the elected invention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1-9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 11-16 of U.S. Patent No. US RE46,792 E. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims are directed to a compound, pharmaceutical composition comprising the compound having the structure 11 or a salt thereof and a pharmaceutically acceptable carrier, and methods of treatment thereof, whereas the instant claims are directed to an ointment composition comprising the same compound. An ointment composition is a pharmaceutical composition containing a base component as a pharmaceutically acceptable carrier. However, the instant claims do not contain any limitations that would structurally differentiate the compositions. The two inventions overlap highly in scope, therefore rendering the instant claims unpatentable. Claims 1-9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. US 10,588,893. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims are directed to a pharmaceutical composition comprising the compound having the structure 11 or a salt thereof and a pharmaceutically acceptable carrier whereas the instant claims are directed to ointment composition Wcomprising the same compound. An ointment composition is a pharmaceutical composition containing a base component as a pharmaceutically acceptable carrier. However, the instant claims do not contain any limitations that would structurally differentiate the compositions. The two inventions overlap highly in scope, therefore rendering the instant claims unpatentable. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-2 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Okada (WO 2007/058338 A2) of record. Okada teaches oxazole compounds of formula (1) or a salt thereof and pharmaceutical compositions (see abstract; page 1, lines 1-2). Okada teaches that, due to their PDE-4 specific inhibitory action, the compounds of the invention can be useful as active ingredient used as prophylactic and therapeutic agents for various disease, including dermatoses such as toxic and allergic eczema, atopic dermatitis (see page 43, lines 5-17). Okada teaches that for external preparations, the compounds may be prepared in, for example ointments, wherein the external preparations can optionally include various carriers, base materials as claimed in the instant claim 2, and additives typically used in external preparations (see page 44, lines 11-16). Okada teaches an exemplary oxazole compound of formula (1) with PDE4 inhibitory activity is: PNG media_image1.png 108 461 media_image1.png Greyscale which is the same compound as claimed in the instant claim 1 (see pages 216-217, Table 11, Ex. No. 230; page 259, Ex. No. 352). The reference teaches a generic group of compounds which embraces applicants’ claimed compound (see above). The claims differ from the reference by reciting a specific specie and a more limited genus than the reference. However, it would have been obvious to one having ordinary skill in the art at the time of the invention to select any of the species of the genus taught by the reference, including those instantly claimed, because the skilled chemist would have the reasonable expectation that any of the species of the genus would have similar properties and, thus, the same use as taught for the genus as a whole. One of ordinary skill in the art would have been motivated to select the claimed compounds from the genus in the reference since such compounds would have been suggested by the reference as a whole. It has been held that a prior art disclosed genus of useful compounds is sufficient to render prima facie obvious a species falling within a genus. In re Susi, 440 F.2d 442, 169 USPQ 423, 425 (CCPA 1971), followed by the Federal Circuit in Merck & Co. v. Biocraft Laboratories, 847 F.2d 804, 10 USPQ 2d 1843, 1846 (Fed. Cir. 1989). Regarding claim 2, Okada does not exemplify an ointment composition comprising an oxazole compound of formula (11) or wherein the ointment comprises the oxazole compound dissolve in a base component. However, it would have been obvious to one of ordinary skill in the art prior to the filing date of the invention to formulate an external ointment preparation containing the oxazole compound based on the guidance provided by Okada. One of ordinary skill in the art would have been motivated to formulate an external ointment preparation containing the oxazole compound based on the guidance provided by Okada in order to provide an external ointment composition for the treatment of skin dermatoses. One of ordinary skill in the art would have had a reasonable expectation of success in formulating an external ointment preparation containing the oxazole compound based on the guidance provided by Okada because Okada teaches the oxazole compounds can be used in external preparations in, for example, the form of ointments. Thus, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art prior to the filing date of the invention. Claims 3-8 are rejected under 35 U.S.C. 103 as being unpatentable over Okada (WO 2007/058338 A2) as applied to claims 1-2 and 9 in the 103 rejection above in view of Masui (US 2011/0212988 A1) of record. Okada is discussed above as applied to claims 1 and 2. Okada does not teach the specific ointment formulations as claimed in the instant claims 3-8. For example, Okada does not teach the oxazole compound dissolved in a base component, wherein the base component comprises a solvent for dissolving the oxazole compound in the solvent, and an ointment based for dispersing or dissolving the solvent in the ointment base as claimed in the instant claims 3-8. Masui teaches a tacrolimus containing ointment having low dermal irritation and excellent stability (see abstract). In particular, Masui teaches the ointment is an o/o type (oil-in-oil type) ointment in which tacrolimus-solubilized triacetin droplets are dispersed in an ointment base as claimed in the instant claims 3, and 6, preferably a mixture of beeswax and petrolatum as claimed in the instant claims 4 and 7 (see abstract). Masui teaches tacrolimus is used in external preparations for the treatment of cutaneous disease such as eczematous dermatitis or atopic dermatitis (see page 1, section [003]; page 3, section [0038]). Petrolatum is a mixture of hydrocarbons as claimed in the instant claim 4. Triacetin is a polar solvent that is liquid at room temperature as claimed in the instant claim 5 (see page 3, section [0034] describing a solution of tacrolimus in triacetin). Regarding claim 8, Masui does not teach the beeswax has to be chemically bleached. It would have been obvious to one of ordinary skill in the art prior to the filing date of the invention to use the ointment base used for the tacrolimus formulation taught by Masui as the ointment base in the ointment comprising the oxazole compound obvious over Okada. One of ordinary skill in the art would have been motivated to use the ointment base used for the tacrolimus formulation taught by Masui as the ointment base in the ointment comprising the oxazole compound obvious over Okada because Masui teaches the ointment has low dermal irritation, excellent stability, and is used for external preparations of the skin for treating cutaneous disease such as atopic dermatitis. One of ordinary skill in the art would have had a reasonable expectation of success in to using the ointment base used for the tacrolimus formulation taught by Masui as the ointment base in the ointment comprising the oxazole compound obvious over Okada because (1) Masui teaches the ointment is suitable for external preparations for the treatment of cutaneous disease such as atopic dermatitis and (2) Okada teaches the oxazole compounds can be used in ointment preparations and that the compounds are useful in treating dermatoses such as atopic dermatitis. Thus, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art prior to the filing date of the invention. Conclusion Claims 1-9 are not allowed. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAHAR JAVANMARD whose telephone number is (571)270-3280. The examiner can normally be reached on Monday-Friday, 9:00-5:00 EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Acevedo-Alstrum can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. /SAHAR JAVANMARD/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Jul 16, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797352
THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
3y 8m to grant Granted Nov 17, 2026
Patent 12788767
USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CHRNA4 MUTATION
3y 9m to grant Granted Nov 10, 2026
Patent 12790339
Bicyclic Compounds and Uses Thereof for the Treatment of Diseases
3y 6m to grant Granted Nov 10, 2026
Patent 12790328
PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING
3y 1m to grant Granted Nov 10, 2026
Patent 12774280
NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS
3y 1m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+34.0%)
2y 10m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 756 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month